Streamlining Biomanufacturing of Personalised Cancer Immunotherapies with Synthetic DNA
13 October 2025 | By
A Synthetic DNA Approach for Speed, Scale & Flexibility
List view / Grid view
13 October 2025 | By
A Synthetic DNA Approach for Speed, Scale & Flexibility
The future of drug discovery lies in an automated world where the workflows for biological assays, chemical synthesis and data analysis are connected by flexible, mobile and modular hardware, integrated with software solutions that will interface with scientists for increased efficiency and productivity (the realisation of Industry 4.0). This article…
Gone are the days where mere data is considered king. We now understand the real value is in proper data management; but how best to harness its value? This article addresses current market options for companies wanting to extract every ounce of knowledge from raw data.
Developers of small molecule pharmaceuticals perform a battery of analytical tests before early clinical trials.
During cell line development, key attributes such as cell productivity, stability and monoclonality are required before progressing cells for manufacturing.
Detailed knowledge of the human genome can provide us with extensive information about the causes of disease and how patients will respond to treatments. In this article, Pushpanathan Muthuirulan explores the concept of genetic testing and the potential for pharmacogenomic testing to transform healthcare.
If not correctly assessed, drug candidates with undesirable safety issues may progress through clinical development, resulting in costly failures later in the development process. Given that many drugs fail in clinical trials due to nephrotoxicity, this article describes the importance of understanding kidney transporter function in drug development, how current…
Do not let the challenges of selecting and analysing bispecific antibodies create havoc in your antibody development.
DNA in the cytoplasm is an indicator of microbial infection, serving as a danger signal and resulting in induction of an innate immune response via the cyclic GAMP synthase (cGAS)/STING (Stimulator of INterferon-sensitive Genes) pathway.
Here, Sheraz Gul highlights some encouraging displays of industry co-operation that aim to counter the global threat posed by COVID-19.
Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. Here, Nikki Withers speaks to Miguel Forte who elaborates on the process…
Therapeutic monoclonal antibodies are proven and effective treatment options but many of the ‘low-hanging fruit’ therapeutics have already been identified.
In this in-depth focus are features on the best data management options currently available and how the future of drug discovery will be connected and fully automated.
The articles in this in-depth focus explain how informatics aids in the development of genomic research and outline the next steps for AI to progress in pharma.
This In-Depth Focus includes articles on antibodies as a treatment for COVID-19, the importance of understanding every aspect of an ADC and the potential of antibodies as a targeted cancer therapeutic.
Included in this In-Depth Focus are articles on why human tissue models are best for testing nephrotoxicity and how genetic and pharmacogenomic testing can improve healthcare options.